Return to homepagePandemic Pact

Development of new COVID-19 therapeutic agents targeting intracellular neoplastic S protein

Grant number: 21K19344

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    2021
    2024

  • Known Financial Commitments (USD)

    $59,150

  • Funder

    KAKENHI

  • Principal Investigator

    Kiyotaka Nishikawa Unspecified

  • Research Location

    Japan

  • Lead Research Institution

    Doshisha University

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    N/A

  • Special Interest Tags

    N/A

  • Study Type

    Unspecified

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

1 Publication linked via Europe PMC

Last Updated:3 days ago

View all publications at Europe PMC

CaMKII-dependent non-canonical RIG-I pathway promotes influenza virus propagation in the acute-phase of infection.